Cargando…
Pam2CSK4-adjuvanted SARS-CoV-2 RBD nanoparticle vaccine induces robust humoral and cellular immune responses
As the global COVID-19 pandemic continues and new SARS-CoV-2 variants of concern emerge, vaccines remain an important tool for preventing the pandemic. The inactivated or subunit vaccines themselves generally exhibit low immunogenicity, which needs adjuvants to improve the immune response. We previo...
Autores principales: | Qiao, Yidan, Zhan, Yikang, Zhang, Yongli, Deng, Jieyi, Chen, Achun, Liu, Bingfeng, Zhang, Yiwen, Pan, Ting, Zhang, Wangjian, Zhang, Hui, He, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780597/ https://www.ncbi.nlm.nih.gov/pubmed/36569949 http://dx.doi.org/10.3389/fimmu.2022.992062 |
Ejemplares similares
-
An efficient and scalable synthesis of potent TLR2 agonistic PAM(2)CSK(4)
por: Kaur, Arshpreet, et al.
Publicado: (2018) -
Molecular Dynamics Studies of Poly(Lactic Acid) Nanoparticles and Their Interactions with Vitamin E and TLR Agonists Pam(1)CSK(4) and Pam(3)CSK(4)
por: Megy, Simon, et al.
Publicado: (2020) -
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
por: Ma, Xiancai, et al.
Publicado: (2020) -
Control of Methicillin-Resistant Staphylococcus aureus Pneumonia Utilizing TLR2 Agonist Pam3CSK4
por: Chen, Yi-Guo, et al.
Publicado: (2016) -
Coinjection with TLR2 Agonist Pam3CSK4 Reduces the Pathology of
Leishmanization in Mice
por: Huang, Lu, et al.
Publicado: (2015)